文献速递妇科产科

林奇综合征相关上皮性卵巢癌的免疫特征分析

Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
PubMed 文献 · Gynecol Oncol · 2021-07-16

该研究分析丹麦HNPCC登记库中30例林奇综合征相关上皮性卵巢癌,评估错配修复缺陷、微卫星不稳定、肿瘤浸润淋巴细胞及B2M和PD-L1表达。29例可评估肿瘤中27例(93.1%)为MMR-d,26例可评估中14例(53.8%)为MSI,半数肿瘤TILs水平高,46.7%存在B2M表达缺失,28.0%表达PD-L1,B2M/PD-L1与MSI/TILs/生存无关联。

要点

  • 林奇综合征相关卵巢癌中MMR-d达93.1%、MSI达53.8%,半数TILs水平高。
  • 46.7%肿瘤B2M表达缺失,28.0%表达PD-L1,二者与生存无关联。
  • B2M缺失常见于TILs低的肿瘤(CD3 p=0.056,CD8 p=0.059)。

核心结论

  • 林奇综合征相关卵巢癌中可见MMR-d、MSI和TILs,提示可能适合检查点抑制剂免疫治疗。
  • B2M缺失介导的免疫逃逸临床影响需更大队列进一步研究。

研究设计与样本

  • 经丹麦HNPCC登记库收集30例林奇综合征相关上皮性卵巢癌并成功分析。
  • 检测MMR-d、MSI、免疫反应(CD3、CD8、CD68)及免疫逃逸机制(B2M、PD-L1),评估标志物间统计关联及B2M/PD-L1与生存的关系。

主要发现

  • 29例可评估肿瘤中27例为MMR-d(93.1%)。
  • 26例可评估肿瘤中14例为MSI(53.8%)。
  • MMR-d/MMR-proficiency与MSI/MSS一致率为60.0%。
  • 半数卵巢肿瘤TILs水平高;B2M表达缺失见于46.7%肿瘤,PD-L1表达见于28.0%病例。
  • B2M/PD-L1与MSI/TILs/生存无关联;B2M缺失常见于TILs低的肿瘤(CD3 p=0.056,CD8 p=0.059)。

临床怎么用

  • 林奇综合征相关卵巢癌可考虑检测MMR-d/MSI以评估检查点抑制剂治疗潜力。
  • B2M缺失可能提示免疫逃逸,需在更大队列中进一步验证其临床意义。

局限性

  • 样本量小(30例),部分指标可评估病例数更少。
  • B2M缺失与低TILs的关联仅达边缘显著性(p=0.056/0.059)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Lynch syndrome is a multi-tumor syndrome characterized by mismatch repair deficiency (MMR-d), microsatellite instability (MSI), and increased tumor-infiltrating lymphocytes (TILs) making these tumors candidates for treatment with immune checkpoint inhibitors. However, response may depend on tumor-induced immune evasion mechanisms, e.g. loss of Beta-2-Microglobulin (B2M) or upregulation of programmed death protein ligand 1 (PD-L1). We investigated the immune response and B2M and PD-L1 expression in Lynch syndrome-associated ovarian cancers. METHODS: We successfully analyzed 30 Lynch syndrome-associated epithelial ovarian cancers collected through the Danish Hereditary Non-Polyposis Colorectal Cancer (HNPCC) register. MMR-d, MSI, immune response (CD3, CD8, and CD68), and immune evasion mechanisms (B2M and PD-L1) were investigated. Statistical associations between these markers were evaluated in addition to survival in relation to B2M/PD-L1. RESULTS: Of the 29 evaluable tumors, 27 were MMR-d (93.1%). Likewise of 26 evaluable tumors, 14 were MSI (53.8%). MMR-d/MMR-proficiency associated with MSI/MSS in 60.0%. Half of the ovarian tumors presented with high levels of TILs. Loss of B2M expression was observed in 46.7% of the tumors, while expression of PD-L1 was seen in 28.0% of the cases. There was no association between B2M/PD-L1 and MSI/TILs/survival. Loss of B2M was often seen in tumors with low TILs (p = 0.056 or p = 0.059 for CD3 and CD8 positive cells, respectively). CONCLUSION: MMR-d, MSI, and TILs are also seen in Lynch syndrome-associated ovarian cancers making these potential candidates for checkpoint-based immunotherapy. The clinical impact from immune evasion through loss of B2M needs to be investigated further in larger cohorts.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rasmussen M, Lim K, Rambech E, et al. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile. Gynecol Oncol. 2021. PMID: 34275654. doi:10.1016/j.ygyno.2021.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。